Potential Cost-Effectiveness of Neratinib Following Trastuzumab Therapy for Treatment of Early-Stage Her2-Positive Breast Cancer

Trastuzumab Therapy ◽

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

Value in Health ◽

10.1016/j.jval.2011.02.916 ◽

2011 ◽

Vol 14 (3) ◽

pp. A165

Author(s):

T.T.T. Nguyen ◽

R. Yagudina ◽

A.U. Kulikov

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

Value in Health ◽

10.1016/j.jval.2014.08.107 ◽

2014 ◽

Vol 17 (7) ◽

pp. A735 ◽

Cited By ~ 1

Author(s):

Nguyen TTC ◽

Nguyen TTT

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-018-0634-5 ◽

2018 ◽

Vol 36 (4) ◽

pp. 505-505

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

Journal of Medical Economics ◽

10.3111/13696998.2014.979938 ◽

2014 ◽

Vol 18 (3) ◽

pp. 173-188 ◽

Cited By ~ 17

Author(s):

C. L. Attard ◽

A. N. Pepper ◽

S. T. Brown ◽

M. F. Thompson ◽

P.-O. Thuresson ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Locally Advanced ◽

Her2 Positive ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2020.26.2.221 ◽

2020 ◽

Vol 26 (2) ◽

pp. 221-221

Author(s):

Phuong T. Tran ◽

Vakaramoko Diaby

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Effectiveness Analysis ◽

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-019-0174-7 ◽

2019 ◽

Vol 17 (1) ◽

Cited By ~ 10

Author(s):

Noga Gershon ◽

Yakir Berchenko ◽

Peter S. Hall ◽

Daniel A. Goldstein

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Sub Saharan Africa ◽

Her2 Positive ◽

Sub Saharan ◽

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer

PLoS ONE ◽

10.1371/journal.pone.0217778 ◽

2019 ◽

Vol 14 (6) ◽

pp. e0217778 ◽

Cited By ~ 2

Author(s):

Ali Hajjar ◽

Mehmet A. Ergun ◽

Oguzhan Alagoz ◽

Murtuza Rampurwala

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Node Negative ◽

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2019.25.10.1133 ◽

2019 ◽

Vol 25 (10) ◽

pp. 1133-1139 ◽

Cited By ~ 2

Author(s):

Naomi R.M. Schwartz ◽

Meghan R. Flanagan ◽

Joseph B. Babigumira ◽

Lotte M. Steuten ◽

Joshua A. Roth

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Effectiveness Analysis ◽

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

PharmacoEconomics ◽

10.1007/s40273-018-0620-y ◽

2018 ◽

Vol 36 (3) ◽

pp. 381-382

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-017-0557-6 ◽

2017 ◽

Vol 36 (1) ◽

pp. 91-103 ◽

Cited By ~ 11

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽